79035-13-5

Basic information

• Product Name: Benzene, 1-chloro-2-nitro-4-(phenylmethoxy)-
• CAS NO: 79035-13-5
• Molecular Formula: C13H10ClNO3
• Molecular Weight: 263.68
• Mol File: 79035-13-5.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: Benzene, 1-chloro-2-nitro-4-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-chloro-2-nitro-4-(phenylmethoxy)-(79035-13-5)
• EPA Substance Registry System: Benzene, 1-chloro-2-nitro-4-(phenylmethoxy)-(79035-13-5)

Safety Data

• Hazardous Substances Data: 79035-13-5(Hazardous Substances Data)

Upstream product

• 10298-80-3 2-chloro-5-methoxynitrobenzene 
• 610-78-6 3-nitro-4-chlorophenol 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 

Downstream Products

• 1181377-07-0 N-(4'-(benzyloxy)-2'-nitrobiphenyl-4-yl)formamide 
• 1181377-23-0 4'-(benzyloxy)-2'-nitrobiphenyl-4-ol 
• 1181376-81-7 tert-butyl 4'-(benzyloxy)-2'-nitrobiphenyl-4-ylcarbamate 
• 1062192-02-2 4-benzyloxy-N-ethyl-2-nitroaniline 
• 474083-59-5 5-benzyloxy-2-(4-t-pentylphenoxy)-nitrobenzene 
• 89553-54-8 C₁₃H₁₄N₂O₃S 
• 122484-75-7 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-5-oxo-1H-1,4-diazepin-1-yl)-5-phenylmethoxy-1H-benzimidazole 
• 122484-74-6 1-(2-ethoxyethyl)-2-(hexahydro-5-oxo-1H-1,4-diazepin-1-yl)-5-phenylmethoxy-1H-benzimidazole 
• 122484-71-3 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-5-phenylmethoxy-1H-benzimidazole 
• 122484-69-9 1-(2-ethoxyethyl)-1,3-dihydro-5-phenylmethoxy-2H-benzimidazol-2-one 
• 122484-70-2 2-chloro-1-(2-ethoxyethyl)-5-phenylmethoxy-1H-benzimidazole 
• 122484-68-8 N¹-(2-ethoxyethyl)-4-phenylmethoxy-1,2-benzenediamine 
• 151384-96-2 6-benzyloxy-1-(N-methyl-2-pyrrolecarboxy)-3-methanesulfonyloxymethylindole 
• 151384-95-1 6-benzyloxy-3-hydroxymethyl-1-(N-methyl-2-pyrrolecarboxy)indole 

Relevant articles and documents

Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds

The duocarmycins belong to a class of agent which has great potential for use in cancer therapy. Their exquisite potency means they are too toxic for systemic use, and targeted approaches are required to unlock their clinical potential. In this study, we

COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR

The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

ORGANIC COMPOUNDS

The present invention relates to novel PDE2 inhibitory compounds of Formula I as described above, their use as pharmaceuticals and pharmaceutical compositions comprising them.